ArticleBMC public health2025
Effect of ambient particulate matter pollution on disease burden globally: a systematic analysis of the global burden of disease study 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Occupational exposure to air pollution and respiratory health among urban street vendors in South India.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundParticulate matter (PM) refers to solid or liquid particles suspended in the atmosphere. These particles can be inhaled during normal respiration, leading to various respiratory diseases including upper respiratory tract infections (URTIs). We comprehensively evaluated the ambient particulate matter pollution-related disease burden.
methodsDue to the particularity of Global Burden of Disease 2021 study (GBD 2021), this study only included data on URTIs attributed to PM, and the age limit was under 5 years old. We first assessed the global and subtype-specific mortality, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) in 2021, along with their age-standardized rates. Additionally, linear regression models were employed to analyze temporal trends in disease burden. We will calculate the corresponding estimated annual percentage change (EAPC) based on the changes in the number of deaths, DALYs and the age-standardized data of both from 1990 to 2021. Cluster analysis was used to examine regional variations in disease burden across Global Burden of Disease study regions. Finally, ARIMA and exponential smoothing (ES) models were applied to forecast disease burden over the next 25 years.
resultsFor indoor PM pollution, in 2021, there were 93.98 deaths per 100,000 population and 9,195.39 DALYs globally in children under 5 years of age. Females exhibited higher risks than males, and regions with a low sociodemographic index (SDI) faced elevated risks. Significant disparities in disease burden were observed across GBD regions and nations. Compared to 1990, mortality and DALYs per 100,000 population declined by 52.28% and 51.38%, respectively. ARIMA projections suggest continued declines in the absolute number of mortality and DALYs for both sexes by 2050, though age-standardized rates may increase for males while decreasing for females. For outdoor PM pollution, 2021 recorded 22.58 deaths per 100,000 population and 2,511.13 DALYs globallyin children under 5 years of age. Females and low-middle SDI regions were at higher risk. Mortality and DALYs per 100,000 population decreased by 55.10% and 48.37% compared to 1990. ARIMA forecasts indicate further reductions in mortality, DALYs, and age-standardized rates for both sexes by 2050.
conclusionParticulate pollutants, particularly indoor PM, pose a significant global public health threat. Tailored strategies based on national conditions are urgently needed to mitigate their impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.